Open an account

AVITA Medical

RCEL · NASDAQ

$13.80+$0.66 (+5.02%)TodayMarket closed ·
Prev close $13.14

About RCEL

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. The company is headquartered in Valencia California, California and currently employs 226 full-time employees. The company went IPO on 2012-03-18. The firm solutions are designed to optimize wound healing, accelerate patient recovery, and improve clinical and economic outcomes across the continuum of acute wound management. Its technologies address critical healing needs arising from burns, traumatic injuries, and surgical repairs, through a portfolio and complementary products that support wound bed preparation, definitive closure, and recovery. Its portfolio includes RECELL and two complementary wound care products, PermeaDerm and Cohealyx. Its RECELL technology platform is an autologous cell harvesting technology that enables clinicians to create a suspension of a patient's own skin cells, called Spray-On Skin, at the point of care. Its PermeaDerm is a biosynthetic wound matrix that manufactures, markets, and distributes in the United States, under multi-year agreements with Stedical.

Employees
226
Headquarters
Valencia California, California
Listed
Mar 18, 2012
Sector
Health Care
Industry
Biotechnology
Website
avitamedical.com

RCEL key statistics

Market cap
426.79M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
347.06K
Volume
422.08K
Open price
$13.29
High today
$14.08
Low today
$13.29
52 Week high
$13.73
52 Week low
$3.22

AVITA Medical (RCEL) at a glance

As of Oct 20, 2026, AVITA Medical (RCEL) shares are priced at $13.80, giving the company a market cap of 426.79M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $13.29 and $14.08. The current price is 3.8% above the day's low and 2.0% below its high.

Volume so far is 422.08K shares, above the average of 347.06K shares a day.

Over the past year AVITA Medical has ranged from $3.22 to $13.73, and now sits 101% of the way up that range.

AVITA Medical met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$0.25 per share against an estimate of -$0.2924.

The average analyst price target is $12.58, 8.8% below the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $12.58
Low
$11.11
Now
$13.80
High
$14.70

RCEL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 7.5% on average.

  1. Q3 FY24: reported -$0.62 per share against an estimate of -$0.4451
  2. Q4 FY24: reported -$0.44 per share against an estimate of -$0.4418
  3. Q1 FY25: reported -$0.53 per share against an estimate of -$0.3927
  4. Q2 FY25: reported -$0.38 per share against an estimate of -$0.253
  5. Q3 FY25: reported -$0.46 per share against an estimate of -$0.2897
  6. Q4 FY25: reported -$0.38 per share against an estimate of -$0.3427
  7. Q1 FY26: reported -$0.35 per share against an estimate of -$0.2856
  8. Q2 FY26: reported -$0.25 per share against an estimate of -$0.2924

RCEL news

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical Inc. - RCEL

  • Press releaseGlobe Newswire

    Bragar Eagel & Squire, P.C. Encourages Soleno, Avita, and Coty Investors to Contact the Firm Regarding Ongoing Investigations

  • Press releaseGlobe Newswire

    Bragar Eagel & Squire, P.C. Encourages Agilon, Soleno, Avita, and Coty Investors to Contact the Firm Regarding Ongoing Investigations

  • Press releaseGlobe Newswire

    Bragar Eagel & Squire, P.C. Encourages Agilon, Soleno, Avita, and Coty Investors to Contact the Firm Regarding Ongoing Investigations

Similar companies

Companies in the same industry as AVITA Medical

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.